WuXi XDC Wins Multiple Awards at Asia-Pacific Biopharma Excellence Awards 2025

WuXi XDC Wins Multiple Awards at Asia-Pacific Biopharma Excellence Awards 2025

SHANGHAI, March 13, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates...

WuXi XDC and AbTis Announce Strategic Partnership to Advance Next-Generation ADCs

WuXi XDC and AbTis Announce Strategic Partnership to Advance Next-Generation ADCs

SHANGHAI and SEOUL, South Korea , March 11, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in...

WuXi XDC and LigaChem Biosciences Strengthen Partnership with Expanded MOU to Accelerate ADC Development

WuXi XDC and LigaChem Biosciences Strengthen Partnership with Expanded MOU to Accelerate ADC Development

SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs)...

menu
menu